SPAIN – Euromed’s pomegranate fruit extract Pomanox may reduce unaesthetic signs of skin ageing such as hyperpigmentation, skin dryness and loss of elasticity, a recent in-vitro study conducted by EURECAT and published in the International Journal of Food Sciences has revealed.
Pomanox is a standardised pomegranate fruit extract obtained from pomegranates cultivated in Mediterranean regions of Spain through sustainable farming.
According to the study, the fruit extract helps in maintaining healthy skin by reducing melanogenesis and oxidative stress while modulating collagen and hyaluronic acid metabolism.
“The results from this proof of concept, in-vitro assay with human foreskin fibroblast cells, therefore suggest that Pomanox is a promising ingredient for nutricosmetic and beauty-from-within applications,” Euromed said in a statement.
Skin photoageing is primarily caused by ultraviolet radiation and can lead to the degradation of skin extracellular matrix components, resulting in hyperpigmentation and loss of skin elasticity.
In this area, polyphenols have become of great interest because of their antioxidant, anti-inflammatory and healthy ageing properties.
Euromed’s Pomanox P30 is standardised to more than 50% total polyphenols and not less than 30% punicalagins α+β, making it an ideal candidate for skin ageing studies.
Multiple assays evaluated the effects of various concentrations of Pomanox on human fibroblast Hs68 cells under normal and UV-induced photoageing conditions.
The study also investigated the inhibitory effects of Pomanox on tyrosinase activity were also investigated.
Analysis showed that under normal conditions, Pomanox significantly increased the collagen and hyaluronic acid metabolism.
“In cells exposed to UV, both preventive and regenerative treatments with Pomanox® positively influenced hyaluronic acid metabolism and decreased ROS (Reactive Oxygen Species) levels,” the report highlighted.
“A significant decrease in levels of MMP-1, the main inhibitor of collagen synthesis, was also verified.”
Pomanox also reported to have showed a significant inhibitory effect on tyrosinase activity, thus potentially reducing hyperpigmentation by decreasing melanin synthesis.
Having shown strong properties of in the modulation of several skin health-associated parameters, Euromed is now preparing to subject Pomanox to clinical study to further investigate and explore these insights.
Pomanox is available in organic form and is also known to provide proven benefits for cardiovascular and metabolic health, sports nutrition, mood and cognitive health.
